Effect of secretory DKK3 on circulating CD56^bright natural killer cells in patients with liver cancer.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2023-06-01 DOI:10.1177/03936155231169796

Da-Hua Liu, Gui-Min Wen, Chang-Liang Song, Pu Xia

{"title":"Effect of secretory DKK3 on circulating CD56bright natural killer cells in patients with liver cancer.","authors":"Da-Hua Liu, Gui-Min Wen, Chang-Liang Song, Pu Xia","doi":"10.1177/03936155231169796","DOIUrl":null,"url":null,"abstract":"Background: Liver cancer seriously threatens human health. Natural killer (NK) cells are an important part of the innate immune system and have strong anti-tumor ability. Immunotherapy based on NK cells has become a hot topic in the treatment of liver cancer.Methods: In this study, we checked the serum DKK3 (sDKK3) and circulating CD56bright NK cells using ELISA and flow cytometry, respectively, in the blood of liver cancer patients. The effect on recombinant human DKK3 (rhDKK3) on CD56bright NK cells was analyzed in vitro.Results: We found low levels of sDKK3 in liver cancer patients and a negative correlation between sDKK3 and circulating CD56bright NK cells. In addition, we found that DKK3 induced the differentiation and improved the cytotoxicity of CD56bright NK cells for the first time. It could be used as an agonist for NK cell-based immunotherapy.Conclusions: Improving the clinical efficacy of NK cells through DKK3 will become a new strategy for cancer immunotherapy.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155231169796","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Liver cancer seriously threatens human health. Natural killer (NK) cells are an important part of the innate immune system and have strong anti-tumor ability. Immunotherapy based on NK cells has become a hot topic in the treatment of liver cancer.

Methods: In this study, we checked the serum DKK3 (sDKK3) and circulating CD56^bright NK cells using ELISA and flow cytometry, respectively, in the blood of liver cancer patients. The effect on recombinant human DKK3 (rhDKK3) on CD56^bright NK cells was analyzed in vitro.

Results: We found low levels of sDKK3 in liver cancer patients and a negative correlation between sDKK3 and circulating CD56^bright NK cells. In addition, we found that DKK3 induced the differentiation and improved the cytotoxicity of CD56^bright NK cells for the first time. It could be used as an agonist for NK cell-based immunotherapy.

Conclusions: Improving the clinical efficacy of NK cells through DKK3 will become a new strategy for cancer immunotherapy.

查看原文本刊更多论文

分泌DKK3对肝癌患者循环CD56bright自然杀伤细胞的影响

研究背景:肝癌严重威胁人类健康。自然杀伤细胞(NK)是先天免疫系统的重要组成部分，具有很强的抗肿瘤能力。基于NK细胞的免疫治疗已成为肝癌治疗的热点。方法:采用ELISA和流式细胞术分别检测肝癌患者血液中DKK3 (sDKK3)和循环CD56bright NK细胞。体外分析重组人DKK3 (rhDKK3)对CD56bright NK细胞的影响。结果:我们在肝癌患者中发现了低水平的sDKK3，并且sDKK3与循环CD56bright NK细胞呈负相关。此外，我们首次发现DKK3诱导CD56bright NK细胞分化并提高细胞毒性。它可以作为NK细胞免疫治疗的激动剂。结论:通过DKK3提高NK细胞的临床疗效将成为肿瘤免疫治疗的新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.